Table 3.
Percent of Approved Prescriptions Dispensed and Predictors of Dispensing after Approval Among Approved Prescriptions
| Number Approved | Dispensed given Approval N (%) | Multivariable Results for Dispensing after Approval ORa (95% CI) | |
|---|---|---|---|
| Overall | 21,259 | 13,891 (65.3%) | |
| Age | |||
| <45 | 469 | 367 (78.2%) | Ref |
| 45–54 | 1736 | 1422 (81.9%) | 1.06 (0.76 – 1.47) |
| 55–64 | 4441 | 3414 (76.9%) | 1.02 (0.75 – 1.39) |
| 65–74 | 9435 | 5687 (60.3%) | 1.11 (0.82 – 1.50) |
| >75 | 5178 | 3001 (58.0%) | 1.02 (0.75 – 1.39) |
| Sex | |||
| Men | 10905 | 6940 (67.0%) | Ref |
| Women | 10354 | 6951 (63.7%) | 0.83 (0.77 – 0.89) |
| Pharmacy | |||
| Retail | 14882 | 9982 (67.1%) | Ref |
| Institutional | 102 | 74 (72.6%) | 1.41 (0.81 – 2.47) |
| Mail order | 218 | 159 (72.9%) | 3.44 (1.82 – 6.49) |
| Specialty | 6057 | 3676 (60.7%) | 0.89 (0.82 – 0.97) |
| Provider type | |||
| General practice | 6740 | 4261 (63.2%) | Ref |
| Cardiology | 11485 | 7539 (65.6%) | 1.18 (1.08 – 1.29) |
| Endocrinology | 997 | 660 (66.2%) | 1.06 (0.87 – 1.28) |
| Other | 2037 | 1431 (70.2%) | 1.49 (1.29 – 1.72) |
| Payor type | |||
| Commercial only | 5111 | 4071 (79.7%) | Ref |
| Government only | 14,236 | 8418 (59.1%) | 0.57 (0.50 – 0.64) |
| Comm + government | 1084 | 762 (70.3%) | 0.68 (0.55 – 0.83) |
| Other | 828 | 640 (77.3%) | 1.17 (0.91 – 1.51) |
| Copay | * | * | Ref: $0 |
| $10 | 0.81 (0.81 – 0.82) | ||
| $20 | 0.66 (0.65 – 0.67) | ||
| $40 | 0.44 (0.43 – 0.45) | ||
| $100 | 0.16 (0.15 – 0.17) | ||
| $200 | 0.06 (0.05 – 0.06) | ||
| $300 | 0.04 (0.03 – 0.04) | ||
| $500 | 0.03 (0.03 – 0.03) | ||
| Time to Approval | |||
| 0–1 day | 9858 | 6620 (67.2%) | Ref |
| 2–7 days | 2829 | 1908 (67.4%) | 1.06 (0.94 – 1.19) |
| 8–14 days | 2263 | 1432 (63.3%) | 0.90 (0.79 – 1.03) |
| 15–31 days | 2647 | 1602 (60.5%) | 0.74 (0.65 – 0.83) |
| >1 mo | 3662 | 2329 (63.6%) | 0.78 (0.70 – 0.87) |
*
Multivariable model results from Copay reflects ultimate out of pocket costs after co-insurance, patient approval program use, and coupon use. Because copay was modelled using restricted cubic splines, representative odds ratios are presented at each copay level. See Figure 2 for absolute dispense rates by copay ranges.